Key result
Empagliflozin cuts CV death or heart failure hospitalization in HFpEF regardless of diabetes status.
Why the study?
Does empagliflozin reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction?
Does empagliflozin reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction?
Empagliflozin reduces the composite risk of cardiovascular death or heart failure hospitalization in patients with HFpEF, independent of diabetes status.
Answers are grounded in this paper and cite their sources.
Supports empagliflozin initiation in HFpEF irrespective of diabetes; extends SGLT2i benefits to preserved ejection fraction.
Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951).
No takes yet. Share an insight, caveat, or question.
Anker et al. (2021) studied this question. Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with preserved ejection fraction, regardless of diabetes status.
Synapse has enriched 10 related papers. Consider them for comparative context: